FRS3: A Potential Drug Target and Biomarker (G10817)

Target Name: FRS3

NCBI ID: G10817

FRS3

FRS3: A Potential Drug Target and Biomarker

Fibroblast growth factor receptor substrate 3 (FRS3) is a protein that is expressed in various tissues throughout the body. It is a member of the Fibroblast growth factor receptor (FGFR) family, which is a group of transmembrane proteins that play a crucial role in cell signaling. FRS3 is a potential drug target and biomarker, and its research has the potential to contribute to the development of new treatments for various diseases.

History of FRS3 Research

FRS3 was first identified in 2005 as a potential drug target by researchers at the University of California, San Diego. They discovered that FRS3 was a protein that was expressed in various tissues, including skin, heart, and brain. The researchers also found that FRS3 was a substrate for the Fibroblast growth factor receptor (FGFR), which is a protein that is involved in cell signaling.

Since its discovery, FRS3 research has continued to evolve. Researchers have identified various functions for FRS3, including its role in cell proliferation, migration, and invasion. They have also found that FRS3 is involved in various signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway.

Drug Target Potential

FRS3's potential as a drug target has led to its investigation as a potential therapeutic agent for various diseases. One of the main advantages of FRS3 as a drug target is its ability to modulate cell signaling pathways. By interacting with FRS3, drugs can either activate or inhibit the signaling pathways that are involved in the disease. This allows for the potential to target specific pathways and minimize potential side effects.

Another advantage of FRS3 as a drug target is its widespread expression in various tissues. This means that even if an effective drug can be developed, it is unlikely to have a significant impact on all cells in the body. This is important because many diseases affect a wide range of cells, and effective treatments need to be available to treat everyone.

FrS3 has also been shown to be involved in various signaling pathways that are involved in cancer. Its role in these pathways makes it a potential target for cancer therapies. Researchers have found that FRS3 is involved in the regulation of cell proliferation, angiogenesis (the formation of new blood vessels), and the development of cancer stem cells. This suggests that targeting FRS3 may be an effective way to treat various types of cancer.

Biomarker Potential

FRS3 has also been identified as a potential biomarker for various diseases. Its involvement in cell signaling pathways makes it an attractive candidate for use as a biomarker. Researchers have found that FRS3 is involved in the regulation of cell growth, differentiation, and inflammation. This suggests that FRS3 may be a useful biomarker for diseases that are characterized by these processes, such as cancer, fibrosis, and inflammation.

FRS3 has also been shown to be involved in the regulation of pain perception. This suggests that targeting FRS3 may be an effective way to treat chronic pain.

Conclusion

FRS3 is a protein that has the potential to be a drug target and biomarker for various diseases. Its involvement in cell signaling pathways makes it an attractive candidate for use as a therapeutic agent. Its widespread expression in various tissues and its potential as a biomarker make it an attractive candidate for use in a variety of diseases. Further research is needed to fully understand the functions of FRS3 and its potential as a drug target and biomarker.

Protein Name: Fibroblast Growth Factor Receptor Substrate 3

Functions: Adapter protein that links FGF and NGF receptors to downstream signaling pathways. Involved in the activation of MAP kinases. Down-regulates ERK2 signaling by interfering with the phosphorylation and nuclear translocation of ERK2

The "FRS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets